ClinicalTrials.gg
RecruitingNCT05790707Updated Jan 23, 2026

EfFect of Ablation of Persistent AtriaL Fibrillation on COgNitive Function in Individuals With Mild Cognitive Impairment

An interventional study of Atrial fibrillation ablation + antiarrhythmic drugs and Antiarrhythmic drug in Mild Cognitive Impairment and Persistent Atrial Fibrillation, sponsored by Poitiers University Hospital. Recruiting at 8 sites in France. Open to participants aged 60 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by Poitiers University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
60 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 189 studies in Cognitive Dysfunction with a site in France — 52 open to participants now, 60 under way, 6 of them phase 3. Cognitive Dysfunction · France.

Planned enrollment
62nd of 139
120 · median 88
Started
2023
with 9 others
No phase
104 of 189
32 open now
Primary completion
2027-01
later than 26 of 59 live
Registered
140th of 189
by date

Among the 189 studies in Cognitive Dysfunction with a site in France, this one is the 62nd largest by planned enrollment of the 139 interventional ones that give a count, is one of 10 that started in 2023, is one of 104 with no phase, reaches primary completion later than 26 of the 59 other live ones, and was the 140th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

52 of the 189 studies in Cognitive Dysfunction with a site in France are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 60 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 189 studies in Cognitive Dysfunction with a site in France, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the effect of catheter ablation of persistent atrial fibrillation on cognitive function in patients with mild cognitive impairment. Participants will be randomized into antiarrhythmic drugs alone or atrial fibrillation ablation + antiarrhythmic drugs.

03

Conditions studied

  • Mild Cognitive Impairment
  • Persistent Atrial Fibrillation
04

Who can participate

Ages eligible
60 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 60 to 80 years
  • Persistent atrial fibrillation
  • Patients with an indication for cardiac rhythm control.
  • score between 18 and 25 points corresponding to mild cognitive impairment
  • Free subject, not under temporary or permanent guardianship and not subject to subordination
  • Subject understanding and accepting the constraints of the study
  • Patient covered by French national health insurance or benefiting from it through a third party
  • Subject has given written consent to the study after having received clear and complete information

Exclusion criteria

Exclusion Criteria:

  • Impossibility to perform the neuropsychological evaluation (communication problems such as hearing loss or aphasia, language barrier)
  • History of clinical stroke
  • Presence of a bruit at carotid auscultation or history of severe carotid stenosis
  • History or suspicion of neurodegenerative disease (Parkinson's disease, Alzheimer's disease, Huntington's disease and amyotrophic lateral sclerosis...), bipolar disorder, schizophrenia, severe depression or amyloidosis
  • Patient with history of previous atrial fibrillation ablation
  • Patient undergoing flutter ablation or atrial tachycardia ablation (not atrial fibrillation ablation)
  • to atrial fibrillation ablation (intracardiac thrombus, severe pulmonary hypertension, mechanical mitral valve prosthesis or contraindication to anticoagulation,…)
  • Contraindication to antiarrhythmic drugs, or to implantable cardiac monitor
  • Patient with very advanced persistent atrial fibrillation, i.e., for more than 3 years or with a left atrial diameter >60 mm in parasternal long axis section or a left atrial volume > 48ml/m2 in echocardiography
  • Subject with a of less than 24 months at study enrolment
  • Inability to consent
  • Persons benefiting from a reinforced protection, namely minors, persons deprived of liberty by a judicial or administrative decision, adults under legal protection, and finally patients in emergency situations
  • Pregnant or breastfeeding women, women at age to procreate and not using effective (hormonal/barrier: oral, parenteral, percutaneous implantable, intrauterine device, or surgical: tubal ligation, hysterectomy, total ovariectomy)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Atrial fibrillation + antiarrhythmic drugs

    The ablation can be done with different sources of energy (radiofrequency, cryoballoon or pulsed field ablation). Different sets of lesions can be performed but the cornerstone is pulmonary vein isolation which will be mandatory. Antiarrhythmic drugs management will be at the operator discretion. Some operators may stop antiarrhythmic drugs after atrial fibrillation ablation.

    Procedure: Atrial fibrillation ablation + antiarrhythmic drugs

  • Active comparator
    Antiarrhythmic drugs alone

    Antiarrhythmic drugs available available are amiodarone, flecainide, propafenone, sotalol. If not previously started, patients randomized to antiarrhythmic drugs arm should start antiarrhythmic drugs therapy within 1 week of randomization. Apart from these recommendations, antiarrhythmic drugs management will be at the operator discretion.

    Drug: Antiarrhythmic drug

Interventions

  • ProcedureAtrial fibrillation ablation + antiarrhythmic drugs

    Atrial fibrillation ablation will be performed with endovascular catheters and will be done either with radiofrequency, cryoballoon or pulsed field ablation. Amiodarone, flecainide, sotalol, propafenone are the anti arrhythmic drugs allowed.

  • DrugAntiarrhythmic drug

    Amiodarone, flecainide, sotalol, propafenone are the anti arrhythmic drugs allowed.

06

What researchers measure

Primary outcomes

  1. Montreal Cognitive Assessmentquestionnaire score evolution 6 months

    To evaluate the effect of "atrial fibrillation ablation + antiarrhythmic drugs" on cognitive function as assessed by the change at the Montreal Cognitive Assessment questionnaire score between randomization (M0) and 6 months after randomization (M6), compared with "antiarrhythmic drugs alone" in patients with persistent atrial fibrillation associated with mild cognitive impairment. The Montreal Cognitive Assessment questionnaire score ranges from 0 to 30. A higher score indicates better cognitive performance.

    Time frame: baseline (randomization) and 6 months after randomization

Secondary outcomes

  1. Baseline characteristics associated with Montreal Cognitive Assessment score improvement

    To define the baseline characteristics associated with Montreal Cognitive Assessment improvement between randomization (M0) and 6 months after randomization (M6) in patients with mild cognitive impairment and persistent atrial fibrillation undergoing atrial fibrillation ablation. The Montreal Cognitive Assessment questionnaire score ranges from 0 to 30. A higher score indicates better cognitive performance.

    Time frame: baseline (randomization) and 6 months after randomization

  2. Changes in different types of cognitive functions

    To assess changes in different cognitive functions measured by a comprehensive neurocognitive assessment between randomization (M0) and 6 months after randomization (M6). The assessed tests are : Free recall/indexed recall 16, WAIS IV "digit memory" subtest, Rapid Frontal Efficiency Battery (BREF) score, Trail Making Test (TMT- GREFEX version), Verbal fluency (GREFEX version) categorical (animals) and literal (letter P), Oral naming of the BETL (Battery for the Evaluation of Language Disorders), STROOP test (GREFEX version), Rey figure, Processing speed index from the WAIS IV.

    Time frame: baseline (randomization) and 6 months after randomization

  3. Montreal Cognitive Assessment questionnaire score evolution 12 months

    To evaluate the effect of "atrial fibrillation ablation + antiarrhythmic drugs" on cognitive function as assessed by the change at the Montreal Cognitive Assessment questionnaire score between randomization (M0) and 12 months after randomization (M12), compared with "antiarrhythmic drugs alone". The Montreal Cognitive Assessment questionnaire score ranges from 0 to 30. A higher score indicates better cognitive performance.

    Time frame: baseline (randomization) and 12 months after randomization

  4. Association between atrial fibrillation burden and cognitive function

    To evaluate the association between atrial fibrillation burden and cognitive function as assessed by the change at the Montreal Cognitive Assessment questionnaire score between randomization (M0) and 12 months after randomization (M12). The Montreal Cognitive Assessment questionnaire score ranges from 0 to 30. A higher score indicates better cognitive performance.

    Time frame: baseline (randomization) and 12 months after randomization

  5. Quality of life Short Form Survey (SF-12)

    To evaluate the effect of "atrial fibrillation ablation + antiarrhythmic drugs" on quality of life assessed by the change at the 12-Item Short Form Survey (SF-12) between randomization (M0), 6 and 12 months after randomization (M6 and M12), compared with "antiarrhythmic drugs alone". Score ranges from 0 to 100, with higher scores indicating better physical and mental health functioning.

    Time frame: baseline (randomization), 6 and 12 months after randomization

  6. Quality of life QOL-AD

    To evaluate the effect of "atrial fibrillation ablation + antiarrhythmic drugs" on quality of life assessed by the change at the Quality of life in Alzheimer's Disease (QOL-AD) questionnaire scores between randomization (M0), 6 and 12 months after randomization (M6 and M12), compared with "antiarrhythmic drugs alone". Score ranges from 13 to 52. The higher the score, the better quality of life the participant has.

    Time frame: baseline (randomization), 6 and 12 months after randomization

07

Study locations

7 of 8 sites recruiting
  • CHU Angers
    Angers, France
    Recruiting
  • University Hospital
    Brest, France
    Recruiting
    • Jacques Mansourati · Contact
  • University Hospital
    Caen, France
    Recruiting
    • Pierre Ollitrault · Contact
  • University Hospital
    Dijon, France
    Recruiting
    • Charles Guenancia · Contact
  • CHU Grenoble
    Grenoble, France
    Recruiting
    • Peggy Jacon · Contact+334 76 76 75 75
  • La Timone
    Marseille, France
    Recruiting
  • University Hospital
    Poitiers, France
    Recruiting
    • Rodrigue Garcia · Contact
  • Centre Cardiologique du Nord
    Saint-Denis, France
    Not yet recruiting
    • Olivier Piot · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Jan 2027, 45 months after the start.

Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 45 months is above that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2023
First posted
Mar 30, 2023
StartActual
Apr 21, 2023
Primary completionEst.
Jan 2027
CompletionEst.
Jul 2027
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05790707
Responsible party
Sponsor
First posted
Mar 30, 2023
Start date
Apr 21, 2023
Primary completion
Jan 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Jan 23, 2026

Study contacts

Rodrigue Garcia
Contact
rodrigue.garcia@chu-poitiers.fr
549443729 ext. +33

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion